Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather
March 13 2018 - 4:35PM
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage
company developing and commercializing novel antibiotics to treat
serious bacterial infections, announced today that it has cancelled
its presentation at the Cowen & Company 38th Annual Health Care
Conference scheduled for Wednesday, March 14, 2018 in Boston, due
to the severe weather that has been forecast for the region.
Company President and CEO Dan Wechsler had been scheduled to speak.
Melinta will post the presentation material to the Events &
Presentations section of its Investors webpage at
http://ir.melinta.com/events.
About Melinta Therapeutics Melinta
Therapeutics, Inc. is the largest pure-play antibiotics company,
dedicated to saving lives threatened by the global public health
crisis of bacterial infections through the development and
commercialization of novel antibiotics that provide new and better
therapeutic solutions. Its four marketed products include Baxdela™
(delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv®
(oritavancin), and Minocin® (minocycline) for Injection. It also
has an extensive pipeline of preclinical and clinical-stage
products representing many important classes of antibiotics, each
targeted at a different segment of the anti-infective market.
Together, this portfolio provides Melinta with the unique ability
to provide providers and patients with a range of solutions that
can meet the tremendous need for novel antibiotics treating serious
infections. Visit www.melinta.com for more information.
For More Information:
Media Inquiries:Amra Maynard(917)
302-2702Amra.maynard@inventivhealth.com
Investor Inquiries:Lisa DeFrancesco(847)
681-3217ldefrancesco@melinta.com
Raj Mistry(312) 801-2051rmistry@melinta.com
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Apr 2023 to Apr 2024